scholarly journals Low thyroid-stimulating hormone as an independent risk factor for Alzheimer disease

Neurology ◽  
2004 ◽  
Vol 62 (11) ◽  
pp. 1967-1971 ◽  
Author(s):  
L. A.D.M. van Osch ◽  
E. Hogervorst ◽  
M. Combrinck ◽  
A. D. Smith
Keyword(s):  
Risk Factor ◽  
Alzheimer Disease ◽  
Independent Risk Factor ◽  
Thyroid Stimulating Hormone ◽  
Stimulating Hormone

scholarly journals Thyroid‐stimulating hormone is an independent risk factor of non‐alcoholic fatty liver disease

JGH Open ◽  
2019 ◽  
Vol 4 (3) ◽  
pp. 400-404 ◽  
Author(s):  
Kazuki Tahara ◽  
Takemi Akahane ◽  
Tadashi Namisaki ◽  
Kei Moriya ◽  
Hideto Kawaratani ◽  
...  
Keyword(s):  
Risk Factor ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Independent Risk Factor ◽  
Thyroid Stimulating Hormone ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease ◽  
Stimulating Hormone

Thyroid-stimulating hormone reference range and factors affecting it in a nationwide random sample

2014 ◽  
Vol 52 (12) ◽  
Author(s):  
Ville L. Langén ◽  
Teemu J. Niiranen ◽  
Juhani Mäki ◽  
Jouko Sundvall ◽  
Antti M. Jula
Keyword(s):  
Risk Factor ◽  
Random Sample ◽  
Reference Range ◽  
Statistical Significance ◽  
Thyroid Stimulating Hormone ◽  
Thyroid Peroxidase ◽  
Healthy Population ◽  
Reference Ranges ◽  
And Gender ◽  
Stimulating Hormone

AbstractPrevious studies with mainly selected populations have proposed contradicting reference ranges for thyroid-stimulating hormone (TSH) and have disagreed on how screening, age and gender affect them. This study aimed to determine a TSH reference range on the Abbott Architect ci8200 integrated system in a large, nationwide, stratified random sample. To our knowledge this is the only study apart from the NHANES III that has addressed this issue in a similar nationwide setting. The effects of age, gender, thyroid peroxidase antibody (TPOAb)-positivity and medications on TSH reference range were also assessed.TSH was measured from 6247 participants randomly drawn from the population register to represent the Finnish adult population. TSH reference ranges were established of a thyroid-healthy population and its subpopulations with increasing and cumulative rigour of screening: screening for overt thyroid disease (thyroid-healthy population, n=5709); screening for TPOAb-positivity (risk factor-free subpopulation, n=4586); and screening for use of any medications (reference subpopulation, n=1849).The TSH reference ranges of the thyroid-healthy population, and the risk factor-free and reference subpopulations were 0.4–4.4, 0.4–3.7 and 0.4–3.4 mU/L (2.5th–97.5th percentiles), respectively. Although the differences in TSH between subgroups for age (p=0.002) and gender (p=0.005) reached statistical significance, the TSH distribution curves of the subgroups were practically superimposed.We propose 0.4–3.4 mU/L as a TSH reference range for adults for this platform, which is lower than those presently used in most laboratories. Our findings suggest that intensive screening for thyroid risk factors, especially for TPOAb-positivity, decreases the TSH upper reference limit.

scholarly journals Relationship of Non Alcoholic Fatty Liver Disease (NAFLD) and Serum Level of Thyroid Stimulating Hormone (TSH) in Normal Reference Range

2021 ◽  
pp. 33-39
Author(s):  
Doaa Ameen Khalil ◽  
Yasser Mohammed Abdul Raouf ◽  
Amal Said Al-Bendary ◽  
Kamal Mohamed Okasha
Keyword(s):  
Risk Factor ◽  
Liver Disease ◽  
Serum Level ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Independent Risk Factor ◽  
Serum Levels ◽  
Thyroid Stimulating Hormone ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Background: Non-alcoholic fatty liver disease (NAFLD) can increase the incidence of cardiovascular disease and hepatocellular carcinoma. Thyroid hormones also play important roles in hepatic lipid metabolism and hepatic insulin resistance. Hypothyroidism is associated with reduced lipolysis and decreased liver uptake of free fatty acids derived from triglycerides. In recent years, the correlation between overt or subclinical hypothyroidism and NAFLD has been discussed. The relationship between NAFLD and thyroid function parameters remains unclear. Aim: We aimed to evaluate the relationship between serum level of Thyroid Stimulating Hormone (TSH) within normal reference range and Non Alcoholic fatty liver Disease (NAFLD). Subjects and Methods: This is a cross sectional case control study on 40 patients with NAFLD and a control group of 20 healthy individuals, who were attendants of Outpatient Clinic of Internal Medicine Department of Tanta University Hospitals and EL-Menshawy General Hospital from February 2018 to the end of January 2019. Results: In the present study, univariate regression analysis showed that serum levels of AST, FT3, FT4 and Anti-TPO were independent risk factors of NAFLD, while in multivariate analysis the only independent risk factor of NAFLD was Anti-TPO serum level. Conclusion: Serum levels of AST, FT3, FT4 and Anti-TPO were independent risk factors of NAFLD in univariate regression analysis, while in multivariate analysis the only independent risk factor of NAFLD was Anti-TPO serum level. Despite the positive correlation between serum TSH level and grade of NAFLD, the study didn’t show serum TSH level as independent risk factor of NAFLD.

Is thyroid-stimulating hormone within the normal reference range a risk factor for atherosclerosis in women?

2011 ◽  
Vol 9 (1) ◽  
pp. 51-57 ◽  
Author(s):  
Anna Boggio ◽  
Fulvio Muzio ◽  
Michela Fiscella ◽  
Domenico Sommariva ◽  
Adriana Branchi
Keyword(s):  
Risk Factor ◽  
Reference Range ◽  
Thyroid Stimulating Hormone ◽  
Normal Reference Range ◽  
Normal Reference ◽  
Stimulating Hormone

scholarly journals CARRIAGE OF THYROID ANTIBODIES AS A RISK FACTOR IN THE DEVELOPMENT AND PROGRESSION OF ENDOCRINE OPHTHALMOPATHY

2017 ◽  
Vol 25 (2) ◽  
pp. 270-278
Author(s):  
V. G. Likhvantseva ◽  
M. S. Afanasyev ◽  
E. A. Rudenko ◽  
С. С. Afanasyev ◽  
E. V. Korosteleva ◽  
...  
Keyword(s):  
Risk Factor ◽  
Clinical Course ◽  
Thyroid Stimulating Hormone ◽  
Thyroid Peroxidase ◽  
Thyroid Autoantibodies ◽  
Thyroid Antibodies ◽  
Increased Risk ◽  
Endocrine Ophthalmopathy ◽  
Toxic Goiter ◽  
Stimulating Hormone

The influence of the carrier of thyroid autoantibodies (to thyroid-stimulating hormone receptor, to thyroglobulin, to thyroid peroxidase) on the clinical course of endocrine ophthalmopathy (EOP), developed on the background of diffuse toxic goiter (139 patients). We studied the role of carrier of monoantibodies and their combinations. It has been proven a direct link between the presence of the analyzed thyroid autoantibodies and the clinical course of EOP. It is shown that the presence of antibodies to thyroid peroxidase and anti-thyroglobulin antibodies is not a lesser important risk factor for the development of EOP in patients with diffuse toxic goiter than the presence of antibodies to the receptor for thyroid-stimulating hormone, and the multiple carriers is associated with more frequent development of active forms of EOP and higher amplitude of inflammation of the orbit. Thus, serological indices and spectrum of thyroid antibodies revealed the depth of systemic disorders of autoimmunity, associated with an increased risk of the development of local autoimmune inflammation in the orbit and can serve as prognostic risk markers of development of highly active and severe forms of EOP.

scholarly journals Predictive Efficacy of Serum Lipoprotein(A) Combined with TSH in Patients with Acute Coronary Syndrome After Coronary Angiography

2021 ◽  
Author(s):  
Kaihang Xu ◽  
Le Wang ◽  
Chuyi Han ◽  
Yingyi Zhang ◽  
Rui Zhang ◽  
...  
Keyword(s):  
Risk Factor ◽  
Coronary Angiography ◽  
Cardiovascular Events ◽  
Independent Risk Factor ◽  
Latex Agglutination ◽  
Thyroid Stimulating Hormone ◽  
Major Adverse Cardiovascular Events ◽  
Lipoprotein A ◽  
Coronary Syndrome ◽  
Endpoint Event

Abstract Backgroud： Elevated lipoprotein(a) [Lp(a)] and thyroid stimulating hormone (TSH) are both associated with coronary artery disease (CAD), but it was controversial in ACS patients. Moreover, patients with elevated plasma TSH tend to have higher levels of lipoprotein. We supposed that patients with elevated LP (a) and TSH may have a adverse prognosis after coronary angiography.Methods: We consecutively recruited 1756 patients who underwent coronary angiography, of which 1473 patients with ACS were eventually enrolled. Major adverse cardiovascular events (MACEs) contained a complex of non-fatal stroke, non-fatal myocardial infarction, ischemic cardiovascular events, and cardiovascular death. According to the occurrence of end events within 27.4 months, the patients were split into two groups: non-endpoint event group (n = 1288) and endpoint event group (n = 185). The date between the two groups were compared. Serum LP (a) was measured by latex agglutination immunoassay (Roche Diagnostics GmbH, Mannheim, Germany).Results: During a median follow-up of 27.4 months, 185 (12.56%) MACEs occurred. Compared with the non-endpoints group，patients in the end-points group had higher level of preoperative LP (a), LDL and TSH (all P<0.05). Multivariate Cox proportional hazard model showed that LP (a) was an independent risk factor for adverse prognosis after coronary angiography in ACS patients, LP (a) > 53.8nmol/L (highest tertile ) predicted 1.704-fold risk for adverse prognosis of ACS (95%CI 1.194~2.433；P＜0.05); Interestingly, patients with elevated LP (a) and TSH concomitantly conferred the highest risk for adverse prognosis OR=3.090 95%CI 1.657~5.765；P＜0.001).Conclusion: LP (a) was an independent risk factor for adverse prognosis after coronary angiography in ACS patients, and the predictive efficacy was enhanced by TSH.

Sign in / Sign up

Export Citation Format

Share Document